Bayer Secures €3 Billion in Apollo Deal for Contraceptives Unit

Bayer has secured €3 billion in financing through an agreement with global investment firm Apollo involving its long-acting reversible contraceptives business. The deal gives Apollo-managed funds a minority, non-controlling stake in a newly created entity that will hold Bayer’s contraceptive portfolio.

Bayer will retain majority ownership and full operational control of the business. This means the company will continue to manage the development, manufacturing and commercial strategy of the products included in the portfolio. The contraceptives unit will also remain fully consolidated within Bayer’s financial reporting.

The portfolio includes several established hormonal intrauterine systems, including Mirena, Kyleena and Jaydess, which is sold as Skyla in some markets. It also includes Jadelle, a contraceptive implant designed to provide long-term pregnancy prevention. These products form an important part of Bayer’s women’s healthcare business and have benefited from growing global demand for long-acting contraceptive options.

Bayer’s intrauterine system products generated approximately €1.37 billion in sales in 2025. The company reported strong growth in the category, supported by higher demand and increased sales volumes. Long-acting reversible contraceptives are often valued because they offer extended protection without requiring patients to remember a daily medication.

The agreement allows Bayer to raise significant capital without selling the business entirely or giving up control of a strategically important portfolio. The company said the financing will help strengthen its capital structure and provide greater financial flexibility. Bayer continues to face financial pressure linked to upcoming debt repayments and ongoing litigation costs, making the additional capital particularly important.

For Apollo, the investment provides access to an established and growing women’s health business while allowing Bayer to continue operating it. The structure reflects a broader trend in which large pharmaceutical companies use private capital to unlock value from specific business units without completing a traditional sale.

The transaction is expected to close in the third quarter of 2026, subject to regulatory approval and standard closing conditions.

The deal highlights the commercial value of contraceptive products and the increasing interest of private investment firms in established pharmaceutical portfolios. However, it may also raise questions about how private investment could influence future decisions around product pricing, innovation and access.

For healthcare professionals, the key issue will be whether this additional financial support helps Bayer expand availability and continue investing in women’s health while maintaining affordability and reliable access for patients worldwide.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com